Welcome to Vernalis Research
We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
Latest news
Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease
Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
Within the collaboration, […]
Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology
Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against […]
Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
PRESS RELEASE, COPENHAGEN 18TH OCTOBER 2023
A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx). The company […]
Our approach
Our established group of experienced scientists is based at our fully-equipped research laboratories in Cambridge, UK.
We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive synthetic organic and medicinal chemistry expertise to enable drug discovery on both established and novel targets.
We have the experience and capabilities for progressing projects from concept to clinic. We have generated lead compounds on enzymes, protein-protein interactions and GPCRs, leading to pre-clinical candidates for Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A.
Our business model
We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical and biotechnology companies, and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Recently disclosed collaborations include those with Servier, Lundbeck, PhoreMost, Asahi Kasei Pharma, Genentech, Dania Therapeutics ApS and Unison Medicines Inc., and we seek additional partnerships.
To find out more, please contact us.